calcitonin gene-related peptide (CGRP) inhibitor
Jump to navigation
Jump to search
Indications
Dosage
- monthly injections[1]
Adverse effects
- appear to be minimal[1]
Mechanism of action
- inhibition of CGRP receptor
- includes monoclonal antibody to CGRP & small molecules gepants able to cross the blood brain barrier
More general terms
More specific terms
- eptinezumab
- erenumab (Aimovig)
- galcanezumab (Emgality)
- gepant
- telcagepant (MK-0974)
- zavegepant (Zavzpret)
Additional terms
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 NEJM JWatch editors Early Results for Experimental Migraine Prevention Meds Look Promising. Physician's First Watch, June 18, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
American Headache Society. Public Release: June 17, 2015 Studies at American Headache Society Meeting show promise in new migraine prevention drugs. CGRP antagonists first mechanism-specific treatments developed to prevent migraine http://www.eurekalert.org/pub_releases/2015-06/tc-saa061515.php